NDRA
ENDRA Life Sciences Inc.
NasdaqCMUSDEQUITY
Healthcare
DELAYED
Strong buy
+55/100
Last price
6.04
▼ 0.27 (4.28%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
6.31
Day high
6.40
Day low
6.03
Volume
14.82K
Market cap
$9.06M
P/E (TTM)
—
52W range
2.96 – 9.85
Trailing performance
Returnvs SPY
1W
+2.72%
+0.8%
1M
-0.17%
-1.3%
3M
+26.89%
+22.4%
6M
+13.11%
-5.1%
YTD
+33.33%
+19.1%
1Y
+5.04%
-11.4%
3Y
-99.69%
-181.9%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on NDRA open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
203.53K
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Mar 2, 26 | TOKMAN ALEXANDER Y Chief Executive Officer |
STOCK | 26.92K | $0 | Direct |
| Mar 2, 26 | JACROUX RICHARD Chief Financial Officer |
STOCK | 13.46K | $0 | Direct |
| Jan 21, 26 | DIGIANDOMENICO ANTHONY Director |
STOCK | 60.32K | $0 | Direct |
| Jan 21, 26 | TOKMAN ALEXANDER Y Chief Executive Officer |
STOCK | 75.00K | $0 | Direct |
| Jan 21, 26 | HARSH MICHAEL JOHN Director |
STOCK | 60.32K | $0 | Direct |
| Jan 21, 26 | BASENESE LOUIS J. Director |
STOCK | 60.32K | $0 | Direct |
| Jan 21, 26 | JACROUX RICHARD Chief Financial Officer |
STOCK | 20.00K | $0 | Direct |
| Oct 10, 25 | DIGIANDOMENICO ANTHONY Director |
STOCK | 70.82K | $500.00K | Direct |
| Jun 11, 25 | DIGIANDOMENICO ANTHONY Director |
STOCK | 5.38K | $0 | Direct |
| Jun 11, 25 | HARSH MICHAEL JOHN Director |
STOCK | 5.38K | $0 | Direct |
| Jun 11, 25 | BASENESE LOUIS J. Director |
STOCK | 5.38K | $0 | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BASENESE LOUIS J. |
Director | 65.71K | Stock Award(Grant) |
DIGIANDOMENICO ANTHONY |
Director | 136.59K | Stock Award(Grant) |
HARSH MICHAEL JOHN |
Director | 65.71K | Stock Award(Grant) |
JACROUX RICHARD |
Chief Financial Officer | 33.46K | Stock Award(Grant) |
TOKMAN ALEXANDER Y |
Chief Executive Officer | 101.93K | Stock Award(Grant) |
Fundamentals
Market cap$9.06M
Enterprise value$7.75M
Revenue (TTM)—
Gross profit—
EBITDA$-6.61M
Net income$-5.92M
EPS (TTM)$-6.26
Free cash flow$-6.73M
Total cash$1.74M
Total debt$429.27K
Book value / share$4.21
Shares outstanding1.50M
Float1.43M
Short % of float2.19%
Dividend yield0.00%
Beta (5Y)-0.08
Valuation & profitability ratios
Trailing P/E—
Forward P/E-1.99
PEG ratio—
Price / sales—
Price / book1.44
EV / revenue—
EV / EBITDA-1.17
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on equity-152.04%
Return on assets-77.32%
Debt / equity6.80
Current ratio7.10
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | — | — |
| Operating revenue | $0 | $0 | $0 | $0 | — | — |
| Gross profit | — | — | — | — | $0 | — |
| Research & development | $1.85M | $3.19M | $5.00M | $6.55M | — | -42.0% |
| Selling, general & admin | $3.91M | $7.63M | $5.52M | $6.60M | — | -48.7% |
| Total operating expense | $5.76M | $10.82M | $10.52M | $13.16M | — | -46.7% |
| Operating income | -$5.76M | -$10.82M | -$10.52M | -$13.16M | — | +46.7% |
| Net interest income | — | -$7.32M | — | — | $0 | — |
| Pre-tax income | -$7.03M | -$11.51M | -$10.06M | -$13.18M | — | +38.9% |
| Tax provision | $0 | $0 | $0 | $0 | — | — |
| Net income | -$7.03M | -$11.51M | -$10.06M | -$13.18M | — | +38.9% |
| Net income to common | -$7.03M | -$11.51M | -$10.06M | -$13.18M | — | +38.9% |
| Basic EPS | -8.93 | -56.94 | -2,766.85 | -7,980.00 | — | +84.3% |
| Diluted EPS | -8.93 | -56.94 | -2,766.85 | -7,980.00 | — | +84.3% |
| EBIT | -$5.76M | -$10.82M | -$10.52M | -$13.16M | — | +46.7% |
| EBITDA | -$5.61M | -$10.61M | -$10.25M | -$12.92M | — | +47.2% |
| Basic shares | 787.02K | 202.11K | 3.64K | 1.65K | — | +289.4% |
| Diluted shares | 787.02K | 202.11K | 3.64K | 1.65K | — | +289.4% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $762.37K | $3.23M | $2.83M | $4.89M | — | -76.4% |
| Cash & short-term investments | $762.37K | $3.23M | $2.83M | $4.89M | — | -76.4% |
| Inventory | — | — | — | $2.64M | $1.28M | — |
| Total current assets | $967.97K | $3.43M | $3.03M | $5.38M | — | -71.8% |
| Property, plant & equipment | $504.46K | $647.29K | $465.87K | $741.47K | — | -22.1% |
| Goodwill & intangibles | $2.01M | $0 | — | — | — | — |
| Total assets | $3.85M | $4.45M | $6.75M | $9.27M | — | -13.4% |
| Total current liabilities | $750.96K | $605.23K | $903.10K | $1.70M | — | +24.1% |
| Current debt | — | — | $28.48K | $28.48K | — | — |
| Long-term debt | — | — | — | — | $28.48K | — |
| Total debt | $492.35K | $584.42K | $394.40K | $546.63K | — | -15.8% |
| Total liabilities | $1.59M | $1.89M | $1.10M | $2.07M | — | -15.8% |
| Retained earnings | -$110.47M | -$103.44M | -$91.93M | -$81.87M | — | -6.8% |
| Shareholder equity | $2.26M | $2.56M | $5.66M | $7.20M | — | -11.7% |
| Working capital | $217.01K | $2.83M | $2.13M | $3.68M | — | -92.3% |
| Net tangible assets | $250.16K | $2.56M | $5.66M | $7.20M | — | -90.2% |
| Shares issued | 1.18M | 536.91K | 5.94K | 1.81K | — | +119.1% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$7.03M | -$11.51M | -$10.06M | -$13.18M | +38.9% |
| Depreciation & amortisation | $157.29K | $206.17K | $275.45K | $234.26K | -23.7% |
| Stock-based compensation | $329.41K | $571.92K | $996.43K | $1.20M | -42.4% |
| Change in working capital | $22.62K | $134.08K | -$923.32K | -$1.03M | -83.1% |
| Operating cash flow | -$5.18M | -$7.40M | -$9.55M | -$12.77M | +30.0% |
| Capital expenditure | -$3.02M | -$16.00K | -$33.88K | -$202.58K | -18,758.0% |
| Investing cash flow | -$3.02M | -$12.80K | -$24.72K | -$202.58K | -23,479.9% |
| Financing cash flow | $5.73M | $7.81M | $7.52M | $8.40M | -26.6% |
| Free cash flow | -$8.20M | -$7.42M | -$9.58M | -$12.97M | -10.6% |
| End cash position | $762.37K | $3.23M | $2.83M | $4.89M | -76.4% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | $0 | — | — |
| Operating revenue | $0 | $0 | $0 | $0 | $0 | — | — |
| Research & development | $233.66K | $776.41K | $508.14K | $432.11K | $381.06K | — | -69.9% |
| Selling, general & admin | $1.25M | $1.40M | $1.11M | $938.59K | $920.03K | — | -10.6% |
| Total operating expense | $1.48M | $2.17M | $1.62M | $1.37M | $1.30M | — | -31.8% |
| Operating income | -$1.48M | -$2.17M | -$1.62M | -$1.37M | -$1.30M | — | +31.8% |
| Pre-tax income | $159.94K | -$1.31M | -$3.17M | -$1.60M | -$1.23M | — | +112.2% |
| Tax provision | $0 | $0 | $0 | $0 | $0 | — | — |
| Net income | $159.94K | -$1.31M | -$3.17M | -$1.60M | -$1.23M | — | +112.2% |
| Net income to common | $159.94K | -$1.31M | -$3.17M | -$1.60M | -$1.23M | — | +112.2% |
| Basic EPS | 0.12 | -1.09 | — | -2.10 | -1.71 | -1.86 | +111.0% |
| Diluted EPS | 0.06 | -1.09 | — | -2.10 | -1.71 | -1.86 | +105.5% |
| EBIT | -$1.48M | -$2.17M | -$1.62M | -$1.37M | -$1.30M | — | +31.8% |
| EBITDA | -$1.44M | -$2.13M | -$1.58M | -$1.33M | -$1.27M | — | +32.3% |
| Basic shares | 1.32M | 1.20M | — | 761.22K | 717.11K | 557.58K | +10.4% |
| Diluted shares | 2.48M | 1.20M | — | 761.22K | 717.11K | 557.58K | +106.3% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $1.74M | $356.46K | $762.37K | $794.04K | $1.81M | +388.1% |
| Cash & short-term investments | $1.74M | $356.46K | $762.37K | $794.04K | $1.81M | +388.1% |
| Total current assets | $5.59M | $536.67K | $967.97K | $1.05M | $1.85M | +941.1% |
| Property, plant & equipment | $444.25K | $464.75K | $504.46K | $544.00K | $583.38K | -4.4% |
| Goodwill & intangibles | $1.90M | $2.43M | $2.01M | — | — | -21.6% |
| Total assets | $7.94M | $3.44M | $3.85M | $1.96M | $2.81M | +131.0% |
| Total current liabilities | $786.58K | $835.44K | $750.96K | $800.31K | $576.64K | -5.8% |
| Total debt | $429.27K | $461.21K | $492.35K | $525.33K | $557.49K | -6.9% |
| Total liabilities | $1.63M | $1.65M | $1.59M | $1.79M | $1.33M | -1.1% |
| Retained earnings | -$111.62M | -$111.78M | -$110.47M | -$107.30M | -$105.70M | +0.1% |
| Shareholder equity | $6.31M | $1.79M | $2.26M | $171.38K | $1.47M | +253.1% |
| Working capital | $4.80M | -$298.77K | $217.01K | $248.40K | $1.28M | +1,706.7% |
| Net tangible assets | $4.40M | -$643.90K | $250.16K | $171.38K | $1.47M | +784.1% |
| Shares issued | 1.50M | 1.24M | 1.18M | 786.90K | 752.39K | +20.9% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Net income | $159.94K | -$1.31M | -$3.17M | -$1.60M | -$1.23M | — | +112.2% |
| Depreciation & amortisation | $39.16K | $39.72K | $39.53K | $39.39K | $32.79K | — | -1.4% |
| Stock-based compensation | $468.92K | $574.45K | $12.88K | $144.72K | $88.76K | — | -18.4% |
| Change in working capital | $47.66K | $439.58K | -$33.84K | -$19.43K | $52.76K | — | -89.2% |
| Operating cash flow | -$927.56K | -$1.12M | -$1.61M | -$1.16M | -$1.11M | — | +17.2% |
| Capital expenditure | — | — | -$3.00M | — | — | -$17.28K | — |
| Investing cash flow | $2.22M | $450.00K | -$3.00M | $0 | $0 | — | +392.7% |
| Financing cash flow | $3.89M | $263.75K | $4.58M | $149.47K | $857.41K | — | +1,376.4% |
| Free cash flow | -$946.23K | -$1.12M | -$4.61M | -$1.16M | -$1.11M | — | +15.5% |
| End cash position | $5.54M | $356.46K | $762.37K | $794.04K | $1.81M | — | +1,454.1% |
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.84 | -1.17 | -39.4% |
| Mar 2026 | -1.23 | -1.09 | +11.4% |
| Dec 2025 | -1.23 | -2.23 | -81.7% |
| Sep 2025 | -1.95 | -2.10 | -7.7% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.84 | 1 | $0 | 0.0% |
| Next quarter | -0.84 | 1 | $0 | 0.0% |
| Current year | -3.54 | 1 | $0 | 0.0% |
| Next year | -3.04 | 1 | $200.00K | 0.0% |
Analyst targets & ownership
Mean target$25.00
High target$25.00
Low target$25.00
Implied upside313.91%
Analyst count1
ConsensusNONE
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders13.57%
Held by institutions17.98%
Institutions holding11
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
6.04
-0.00% from price
SMA 20
5.89
+2.49% from price
SMA 50
5.25
+15.13% from price
SMA 100
5.17
+16.82% from price
SMA 200
4.78
+26.23% from price
EMA 12
5.99
+0.89% from price
EMA 26
5.78
+4.53% from price
EMA 50
5.51
+9.57% from price
RSI (14)
54.6
Neutral
MACD (12,26,9)
0.21
Hist -0.02
ATR (14)
0.49
8.04% of price
Realised vol 30D
106.0%
Annualised
Bollinger upper
6.50
20, 2σ
Bollinger lower
5.29
20, 2σ
50 / 200 cross
Golden
5.25 vs 4.78
Trend bias
Above 200
+26.23%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.28
More volatile than market
Correlation to SPY
0.15
Largely independent
Realised vol 30D
106.0%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-59.9%
Peak to trough
Max drawdown 5Y
-100.0%
Peak to trough
ATR 14
0.49
8.04% of price
Beta (reported)
-0.08
5Y monthly, from filing
Short interest
Shares short
31.34K
Prior 30.08K
Change vs prior
+4.2%
Shorts adding
% of float
2.19%
Normal
% of shares out
2.09%
Against total outstanding
Days to cover
0.7
Liquid
Float
1.43M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jun 1, 26 | Ascendiant Capital | MAINTAINED | Buy | Buy |
| Dec 8, 25 | Ascendiant Capital | MAINTAINED | Buy | Buy |
| Sep 22, 25 | Ascendiant Capital | MAINTAINED | Buy | Buy |
| May 30, 25 | Ascendiant Capital | MAINTAINED | Buy | Buy |
| Apr 21, 25 | Ascendiant Capital | MAINTAINED | Buy | Buy |
| Jun 7, 24 | Ascendiant Capital | MAINTAINED | Buy | Buy |
| Mar 31, 23 | HC Wainwright & Co. | MAINTAINED | — | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split1:35
Split dateNov 7, 2024
SEC filings
Offering Registrations
S-4 · 2026-10-02
Corporate Changes & Voting Matters
8-K · 2026-10-01
Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions
425 · 2026-09-25
Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions
425 · 2026-09-14
Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions
425 · 2026-09-09
Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions
425 · 2026-08-21
Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions
425 · 2026-08-20
Corporate Changes & Voting Matters
8-K · 2026-08-17
Headlines
ENDRA Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business Update
Business Wire · 51d ago
Join the Live Investor Webinar for Noble Africa, the Proposed ASP Isotopes Spin-Out Creating a Public Helium Company
Business Wire · 82d ago
Join the Live Investor Webinar for Noble Africa, the Proposed ASP Isotopes Spin-Out Creating a Public Helium Company
ACCESS Newswire · 82d ago
ENDRA Life Sciences Gains Compliance With Nasdaq Listings Rule
MT Newswires · 90d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.